Market closed
23andMe/$ME
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About 23andMe
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
Ticker
$ME
Sector
Trading on
Industry
Health Care Providers & Services
Headquarters
Employees
571
Website
23andMe Metrics
BasicAdvanced
$83M
Market cap
-
P/E ratio
-$24.95
EPS
1.26
Beta
-
Dividend rate
Price and volume
Market cap
$83M
Beta
1.26
52-week high
$5.00
52-week low
$2.66
Financial strength
Current ratio
1.235
Quick ratio
0.831
Long term debt to equity
61.241
Total debt to equity
70.331
Management effectiveness
Return on assets (TTM)
-26.55%
Return on equity (TTM)
-169.23%
Valuation
Price to revenue (TTM)
0.412
Price to book
0.82
Price to tangible book (TTM)
1.6
Price to free cash flow (TTM)
-0.612
Growth
Revenue change (TTM)
-28.47%
Earnings per share change (TTM)
71.45%
3-year revenue growth (CAGR)
-9.24%
3-year earnings per share growth (CAGR)
12.95%
23andMe News
AllArticlesVideos
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation
GlobeNewsWire·3 days ago
23andMe Holding Co. (ME) Q2 2025 Earnings Call Transcript
Seeking Alpha·1 week ago
23andMe cuts 40% of staff in restructuring
TechCrunch·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for 23andMe stock?
23andMe (ME) has a market cap of $83M as of November 23, 2024.
What is the P/E ratio for 23andMe stock?
The price to earnings (P/E) ratio for 23andMe (ME) stock is 0 as of November 23, 2024.
Does 23andMe stock pay dividends?
No, 23andMe (ME) stock does not pay dividends to its shareholders as of November 23, 2024.
When is the next 23andMe dividend payment date?
23andMe (ME) stock does not pay dividends to its shareholders.
What is the beta indicator for 23andMe?
23andMe (ME) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.